Skip to content

Clinical Evaluation of Circulating Tumor Cells in Pancreatic Cancer

Clinical Evaluation of Circulating Tumor Cells in Pancreatic Cancer

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500107194
Enrollment
Unknown
Registered
2025-08-06
Start date
2025-08-07
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

Sponsors

Fudan University Shanghai Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18–85 years; 2. Newly diagnosed as resectable pancreatic cancer or determined to be resectable after neoadjuvant therapy; 3. Undergoing first resection; 4. Postoperative pathological diagnosis confirmed as pancreatic ductal adenocarcinoma; Signed the informed consent form and is willing to comply with the sampling, evaluation and follow-up requirements of this study.

Exclusion criteria

Exclusion criteria: 1. Having a history of other cancers in the past or at present; 2. Not undergoing first resection; 3. Having participated in a drug clinical trial during the same period (30 days before or after); 4. Other circumstances deemed unsuitable for participation in this study by the researchers.

Design outcomes

Primary

MeasureTime frame
CTC;

Countries

China

Contacts

Public ContactYu Xianjun

Fudan University Shanghai Cancer Center

yuxianjun@fudanpci.org+86 183 0166 9875

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026